{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:14:29Z","timestamp":1783743269897,"version":"3.55.0"},"reference-count":15,"publisher":"American Psychiatric Association Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PS"],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.1176\/appi.ps.20260203","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:47:58Z","timestamp":1779288478000},"page":"693-696","source":"Crossref","is-referenced-by-count":0,"title":["When Off-Label Ketamine Meets Direct-to-Consumer Telehealth: Liability Risks and Ethical Responsibilities"],"prefix":"10.1176","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-0136","authenticated-orcid":false,"given":"Joshua","family":"Mitchell","sequence":"first","affiliation":[{"name":"Ethical Legal Implications of Psychedelics in Society Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bregman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, School of Medicine and Health Sciences, George Washington University, Washington, DC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renuka","family":"Surujnarain","sequence":"additional","affiliation":[{"name":"Bloomberg School of Public Health, Johns Hopkins University, Baltimore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Sisti","sequence":"additional","affiliation":[{"name":"Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Ethical Legal Implications of Psychedelics in Society Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"e_1_3_2_2_2","volume-title":"John and Linda Ward v Mindbloom, Inc, et al, No 25CV008485-730 (NC Super Ct Pitt County Oct 21, 2025)","unstructured":"John and Linda Ward v Mindbloom, Inc, et al, No 25CV008485-730 (NC Super Ct Pitt County Oct 21, 2025)"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.04.017"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.9.1021"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21111086"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4945"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-014-0527-z"},{"key":"e_1_3_2_8_2","volume-title":"FDA Warns Patients and Health Care Providers About Potential Risks Associated With Compounded Ketamine Products, Including Oral Formulations, for the Treatment of Psychiatric Disorders","year":"2023","unstructured":"FDA Warns Patients and Health Care Providers About Potential Risks Associated With Compounded Ketamine Products, Including Oral Formulations, for the Treatment of Psychiatric Disorders. Silver Spring, MD, US Food and Drug Administration, 2023. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1353\/hcr.2007.0039"},{"key":"e_1_3_2_10_2","first-page":"43","article-title":"Physicians\u2019 liability for off-label prescriptions","volume":"21","author":"Riley JB","year":"2007","unstructured":"Riley JB Jr, Basilius PA: Physicians\u2019 liability for off-label prescriptions. Nephrol News Issues 2007; 21:43\u201344, 46\u201347","journal-title":"Nephrol News Issues"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-023-01425-9"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000452"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.42210"},{"key":"e_1_3_2_14_2","article-title":"Carefluencer culture\u2014when wellness trends become medical threats","author":"Samuels J","year":"2025","unstructured":"Samuels J: Carefluencer culture\u2014when wellness trends become medical threats. Forbes, June 10, 2025. https:\/\/www.forbes.com\/sites\/johnsamuels\/2025\/06\/10\/is-elon-musks-ketamine-use-encouraging-dangerous-self-medication","journal-title":"Forbes"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9889"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30102-5"}],"container-title":["Psychiatric Services"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:00:45Z","timestamp":1783742445000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ps.20260203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.1176\/appi.ps.20260203"],"URL":"https:\/\/doi.org\/10.1176\/appi.ps.20260203","relation":{},"ISSN":["1075-2730","1557-9700"],"issn-type":[{"value":"1075-2730","type":"print"},{"value":"1557-9700","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}